Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study

Clinical Cancer Research

Volumn 14, Issue 9, 2008, Pages 2763-2767

  Berthold, Dominik R ^a   Pond, Gregory R ^a   Roessner, Martin ^b   De Wit, Ronald ^c   Eisenberger, Mario ^d   Tannock, Ian F ^a,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b SANOFI   (France)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TAXOID;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; AGED; BLOOD; CONTROLLED STUDY; MORTALITY; PROSTATE TUMOR;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; MITOXANTRONE; PAIN; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TAXOIDS;

EID: 49649115490     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0944     Document Type: Article

References (13)

1. 1.Tannock IF, deWit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
2. Melzack R.The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975:1:277 - 99.
3. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-9.
4. Esper P, Mo F, Chodak G, et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997;50:920-8.
5. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983;1:710-9.
6. Berthold DR, Pond GR, deWit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival of the TAX 327 study. J Clin Oncol 2008;26:242-5.
7. Dowling AJ, PanzarellaT, Ernst DS, et al. A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer. Ann Oncol 2001;12:773-8.
8. Scher HI, Kelly WM, Zhang ZF, et al. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst1999;91:244-51.
9. Sridhara R, Eisenberger MA, Sinibaldi VJ, et al. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 1995;13:2944-53.
10. Collette L, Burzykowski T, Schroder FH. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. EurJCancer 2006;42:1344-50.
11. Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006;98:516-21.
12. Armstrong AJ, Garett-Mayer E.YangYO, et al. Prostate-specific antigene and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007;25:3965-70.
13. Olbert PJ, Hegele A, Kraeuter P, Heidenreich A, Hofmann R, Schrader AJ. Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. Anticancer Drugs 2006;17:993-6.